Rosol Michael Stanley 4/A
4/A · NAVIDEA BIOPHARMACEUTICALS, INC. · Filed Mar 8, 2022
Insider Transaction Report
Form 4/AAmended
Rosol Michael Stanley
Chief Medical Officer
Transactions
- Award
Stock Option
2021-12-27$0.00/sh+100,000$100→ 100,000 totalExercise: $1.08Exp: 2031-12-27→ Common Stock (100,000 underlying)
Footnotes (1)
- [F1]Stock options granted pursuant to Issuer's 2014 Amended and Restated Stock Incentive Plan, which vest quarterly over a four-year period beginning on April 1, 2022.